LENZ has announced an exclusive licensing and commercialisation agreement with Lotus Pharmaceutical of Taiwan.

The executive order aims to cut US prescription drug costs by linking them to the lowest prices paid internationally.

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

Isolator lines present several significant advantages for large-scale aseptic filling, as Marcel Langner of IDT Biologika ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Haya Therapeutics has secured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart ...

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.

Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma’s ...

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...